Rankings
▼
Calendar
NVAX Q1 2025 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$667M
+610.3% YoY
Gross Profit
$653M
97.9% margin
Operating Income
$516M
77.3% margin
Net Income
$519M
77.8% margin
EPS (Diluted)
$2.93
QoQ Revenue Growth
+654.9%
Cash Flow
Operating Cash Flow
-$186M
Free Cash Flow
-$187M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$1.4B
Stockholders' Equity
-$76M
Cash & Equivalents
$263M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$667M
$94M
+610.3%
Gross Profit
$653M
$45M
+1348.6%
Operating Income
$516M
-$139M
+471.6%
Net Income
$519M
-$148M
+451.5%
Revenue Segments
Nuvaxovid Sales
$608M
91%
Royalties and Other
$45M
7%
Supply Sales
$14M
2%
Geographic Segments
CANADA
$576M
86%
Rest of the World
$43M
6%
UNITED STATES
$39M
6%
Europe
$8M
1%
← FY 2025
All Quarters
Q2 2025 →